mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. - Wikidata - wikimedia - TriplyDB

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

http://www.wikidata.org/entity/Q34394233

about

PI3K and AKT: Unfaithful Partners in Cancer mTOR regulates the expression of DNA damage response enzymes in long-lived Snell dwarf, GHRKO, and PAPPA-KO mice Cancer metabolism as a central driving force of glioma pathogenesis mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling.MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape.Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).The mTOR signaling pathway as a treatment target for intracranial neoplasms Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance.Proximity ligation assay evaluates IDH1R132H presentation in gliomas Oncolytic adenoviruses: A thorny path to glioma cure Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.Disruption of NF-κB signaling by fluoxetine attenuates MGMT expression in glioma cells.S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells.mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment.Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy Control of glioma cell migration and invasiveness by GDF-15 DEPTOR suppresses the progression of esophageal squamous cell carcinoma and predicts poor prognosis.SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells.mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)Deptor: not only a mTOR inhibitor.Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy.MGMT testing--the challenges for biomarker-based glioma treatment.Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma.Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?K27M-mutant histone-3 as a novel target for glioma immunotherapy.MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.DNA methylation in adult diffuse gliomas.mTORC1 and mTORC2 in cancer and the tumor microenvironment.The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas.Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy.Prognostic relevance of miRNA-155 methylation in anaplastic glioma.PTRF suppresses the progression of colorectal cancers.NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy.LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene.Cell surface GRP78 promotes tumor cell histone acetylation through metabolic reprogramming: a mechanism which modulates the Warburg effect.Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression.Glioblastoma in elderly patients: solid conclusions built on shifting sand?mTOR Cross-Talk in Cancer and Potential for Combination Therapy.

P2860

Q26781367-534232D6-A4D9-41AB-85E4-FC7F1944DB87 Q28278550-B31A1AE4-9F52-461B-9AFC-96BE689AA06F Q33847616-1467C89E-FB24-487C-B075-CE78228C1633 Q33884658-9292D560-1F0D-4E86-9118-D220B2DC389F Q34365811-AB5A1795-7DCE-43FE-804E-996B6581243A Q34478948-3111C029-16DD-4D7F-B882-F4A0CAA3BA1A Q34886859-69908C83-4312-4A59-9CA1-5B89BFC5224C Q34974398-CCB75DF4-4789-41FB-A8F3-3B1022FCEACD Q35056736-3373ECCA-B4EB-44D0-8082-38C23E4B600A Q35077747-2AD09776-F1ED-4429-A013-99338ABFBD3A Q35910243-387C8AC9-2149-4855-84CD-03D6035C68FF Q35997569-39FCFBB4-7B69-4FD1-A3CC-209A33848833 Q36095183-9048FFEC-9B18-4235-91D9-8127010F59AB Q36256815-9FBB336D-0CA0-4D45-A548-932722BA100A Q36544494-EAE5ED5C-0548-45D6-A847-DEA93CFFCF3A Q36545796-73E77C79-718C-447A-8DAA-6D85EDCD3B15 Q36946604-AA6215C2-F21D-4693-8F34-BFDDAF27241E Q37046569-EE9E1855-25C0-4ADD-B890-9C5379884F64 Q37085905-DCA26AEB-0540-4649-AB32-EA3E438D5B5E Q37269265-A6A89FA1-7904-4A09-9A05-369825C27537 Q37295241-0E769388-6171-45D7-BCC0-9E4DA9CF90AF Q37586507-83B63E82-B265-4293-9582-4D120525C2F2 Q37636690-D71856CB-8DD1-4A5E-9303-5994AE0A93DC Q38218848-221B8DB2-1A10-4E46-9912-65F7C80AFEBE Q38265614-DB3C11CD-070B-4873-882E-CBE3D4C1D096 Q38364234-CF9E701E-1D7A-4ABC-9351-2736FFDA2C0A Q38622784-5FC558F6-090C-4EE3-9164-036025BEA2F5 Q38692922-8B7DE410-4160-49DF-BEBA-C2D1488A5934 Q38861997-EB9EDF05-F798-4C17-9792-09B922947D75 Q38982579-06DB45E8-61F2-4DB8-8F99-DA77E0C7EA72 Q38998436-CE3D8195-3265-4004-8331-B93139D78F62 Q39110234-8D3C12CE-B34E-4F0C-B29C-2CBCD1692A45 Q39158460-66BFF9CE-D3E8-47FD-97E3-7AADFBB1064A Q41472038-7860FBE1-3A20-4BB5-B5BE-F4151DCAB86A Q41911962-F7036052-B120-457B-8221-F313AD18F516 Q42315795-BFE4C510-527E-40B7-8E6A-BD14BA6CFDDB Q47096429-86A20FF9-9058-4ED8-860C-42A30D0F530E Q47232136-E4D1F367-3336-4D5C-A703-0CF0ECF7056D Q47827482-E7E1FE18-4C1E-4F06-B681-25122EE708EF Q48530866-A04B15E5-937F-4D56-AC99-0CE32CA4282B

P2860

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

http://www.wikidata.org/entity/Q34394233

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

@ast

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

@en

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

@nl

type

label

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

@ast

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

@en

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

@nl

prefLabel

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

@ast

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

@en

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

@nl

P1433

Q34394233-8A918156-5536-4F3E-A032-9F62557979E6

P1476

Q34394233-D9EB23CC-2542-4EF0-8B22-99B1374DD046

P2093

Q34394233-02AD1F6A-2967-4C59-B4DB-78944D180F22

Q34394233-0649C022-C7CF-4E5C-A1BF-582D422E95C4

Q34394233-09F400A7-4EB2-4183-95C2-64701F268D77

Q34394233-0E409E0A-4CE9-4C48-A8D9-84018627DE8E

Q34394233-17394145-2982-422A-A538-AF0FACFC4474

Q34394233-17994A9F-FADC-4454-AFF4-8E9EB5777C71

Q34394233-38B5CE8E-23C4-47F4-AF0B-21B28FDFC2C4

Q34394233-67E9A9F9-3D27-4FB6-AF96-294F034AEBAA

Q34394233-6C176CF0-AFA7-42E1-9EFA-A8C5B3134238

Q34394233-6D13A906-0A2A-4114-B13E-1FE4FB03D9EA

P2860

Q34394233-0137C234-6A65-4293-83B8-BF4C9F49842F

Q34394233-0EFB8159-B078-41B1-B18F-1ECC688AF413

Q34394233-0F29860F-784A-4A26-A9A5-B9B2FF4CFAFF

Q34394233-224FD87C-8FAB-4DD7-9FED-F74471E6BA20

Q34394233-437C2CBB-953B-4BD9-A192-EC9245187B78

Q34394233-47F94487-68A8-4A6F-A032-669F8A21D15A

Q34394233-4A113103-4886-4540-8662-BE4181645583

Q34394233-4B9902B3-9B0B-470F-BEF8-0FF02470226F

Q34394233-4CDEFF5B-8552-40B3-8C4C-BCBED4784337

Q34394233-514C3BE6-ECF3-405E-AF8A-2BF96EAA5AAE

P304

Q34394233-E000EC63-609B-482F-A4BE-638EDAA65249

P31

Q34394233-92FFE8B8-C945-4F64-81BE-D3AF331CC57B

P356

Q34394233-040DDF73-4712-4509-BB07-23034D43BA66

P407

Q34394233-3699CE40-B08E-4B79-837C-D188084B50EF

P433

Q34394233-EBB07DB3-5388-4BA2-ADCA-D4861BA3A1DC

P478

Q34394233-E0D8BC3E-F42E-451D-845B-4FE856D2FCBC

P50

Q34394233-14ACB636-C730-4557-8AE9-144157368325

Q34394233-2B2C430B-65B3-448F-B734-E8784A865C47

Q34394233-3502C3CF-AC9D-4365-B363-D2603CE2A951

Q34394233-87A752E5-5A6C-4D82-8BFB-E4834237E048

Q34394233-971B08C3-2FEE-42D7-97B3-9738D1F49B12

Q34394233-A2B6BBB2-65BC-4E3D-9415-6B946D3744E1

Q34394233-C50740E9-7355-4C81-9CDC-AE1BE7704042

Q34394233-C92FE59D-06DC-4A19-AA25-C7A9863A1BA4

Q34394233-CCD86F41-4162-4281-A698-0EC64D97293B

P577

Q34394233-3FBE446E-398F-448A-A969-9F64586BE503

P5875

Q34394233-6FC87901-351B-4E3D-AEC3-D59F09A880A9

P698

Q34394233-71C8BDF2-7E3C-4107-BA60-8E173B091FBF

P921

Q34394233-78932443-5984-4EC9-BB87-A439B05ADDDB

P932

Q34394233-91E1BC94-71F6-413B-A8A2-93509D5473A1

P356

PNAS.1314469111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

@en

P2093

Amir Abdollahi

http://www.w3.org/2001/XMLSchema#string

Christoph Meisner

http://www.w3.org/2001/XMLSchema#string

Florian Lang

http://www.w3.org/2001/XMLSchema#string

Frank Winkler

http://www.w3.org/2001/XMLSchema#string

Gergely Solecki

http://www.w3.org/2001/XMLSchema#string

Jonas Blaes

http://www.w3.org/2001/XMLSchema#string

Manfred Jugold

http://www.w3.org/2001/XMLSchema#string

Marcus Czabanka

http://www.w3.org/2001/XMLSchema#string

Markus Weiler

http://www.w3.org/2001/XMLSchema#string

Matthias Osswald

http://www.w3.org/2001/XMLSchema#string

P2860

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Carcinogenic nickel induces genes involved with hypoxic stress

Hypoxia--a key regulatory factor in tumour growth

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Emerging insights into the molecular and cellular basis of glioblastoma.

Mechanisms of chemoresistance to alkylating agents in malignant glioma.

Hypoxia helps glioma to fight therapy.

The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications.

Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment.

P304

409-414

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1314469111

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Martina Schnölzer

Michael Platten

Andreas von Deimling

Martin Bendszus

P577

2013-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259456780

http://www.w3.org/2001/XMLSchema#string

P698

24367102

http://www.w3.org/2001/XMLSchema#string

P921

P932

3890826

http://www.w3.org/2001/XMLSchema#string